FDA indicated that approval of MAT2203 as a first-line treatment for invasive aspergillosis will require an adequately powered study with an active control group and an all-cause mortality non-inferiority margin of 10%.

FDA provided alternative trial designs which include the highest-need patients, aligning with growing positive treatment success in Matinas’ Compassionate/Expanded Use Program as highlighted by a recent case update from Nationwide Children’s Hospital

Internal RNAi programs demonstrate compelling in vitro activity; in vivo studies evaluating biological activity of LNC oral formulations of small oligonucleotides expected in second half of 2023

The Company believes its cash position is sufficient to fund planned operations into the third quarter of 2024.